Schiller, Gary J <br/><br/>
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2010 
 - 815-21 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2009.24.2008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Alkylating--administration & dosage<br/>Comorbidity<br/>Europe--epidemiology<br/>Female<br/>Gene Expression Regulation, Leukemic<br/>Heart Diseases--mortality<br/>Humans<br/>Hydrazines--administration & dosage<br/>Infusions, Intravenous<br/>Kaplan-Meier Estimate<br/>Karyotyping<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Liver Diseases--mortality<br/>Lung Diseases--mortality<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Sulfonamides--administration & dosage<br/>Treatment Outcome<br/>United States--epidemiology